(Q35000470)

5 August 2017

0 references

1 reference

title

Treatment of xerostomia: a systematic review of therapeutic trials (English)

1 reference

5 August 2017

1 reference

Michael T Brennan

1

1 reference

5 August 2017

Galib Shariff

series ordinal

2

1 reference

5 August 2017

Peter B Lockhart

series ordinal

3

1 reference

5 August 2017

Philip C Fox

series ordinal

4

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Dental clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

46

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

847-856

1 reference

Xerostomia: evaluation of a symptom with increasing significance

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Subjective reports of xerostomia and objective measures of salivary gland performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Salivary gland dysfunction: a review of systemic therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Rating the quality of evidence for clinical practice guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Use of orally administered anhydrous crystalline maltose for relief of dry mouth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Primary Sjögren's syndrome treated with Efamol/Efavit. A double-blind cross-over investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Lacrimal and salivary secretion in Sjögren's syndrome: the effect of systemic treatment with bromhexine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Electrical stimulation of salivary flow in patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Effects of pilocarpine on salivary flow in patients with Sjo¨gren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A placebo controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Patients with primary Sjögren's syndrome treated for two months with evening primrose oil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Sjorgren's syndrome treated with bromhexine: a randomised clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Sjögren's syndrome treated with bromhexine: a reassessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Treatment of radiation side effects with oral pilocarpine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Acupuncture treatment of patients with radiation-induced xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Comparison of the effect of the linseed extract Salinum and a methyl cellulose preparation on the symptoms of dry mouth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Comparison between saliva stimulants and a saliva substitute in patients with xerostomia and hyposalivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

Subjective and clinical evaluation of oral lubricants in xerostomic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

The effect of acupuncture on salivary flow rates in patients with xerostomia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

The effect of a chewing gum on salivary secretion, oral mucosal friction, and the feeling of dry mouth in xerostomic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-8532%2802%2900023-X

10.1016/S0011-8532(02)00023-X

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference